Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zelpultide Alfa for Prevention of Bronchopulmonary Dysplasia in Preterm Neonates
NCT06897839Phase 3Recruiting
- Sponsor
- Airway Therapeutics
- Start
- Feb 2025
- Primary completion
- Mar 2028
- Modality
- Replacement Enzymes
- Countries
- 8
01
Overview
A Phase 3 trial of zelpultide alfa in bronchopulmonary dysplasia (BPD), sponsored by Airway Therapeutics. Started Feb 2025; status: recruiting.
02
Drugs
zelpultide alfa
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT06897839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06897839.